Urinary Bladder Neoplasms
"Urinary Bladder Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the URINARY BLADDER.
| Descriptor ID |
D001749
|
| MeSH Number(s) |
C04.588.945.947.960 C12.758.820.968 C12.777.829.813 C13.351.937.820.945 C13.351.968.829.707
|
| Concept/Terms |
Urinary Bladder Neoplasms- Urinary Bladder Neoplasms
- Neoplasm, Urinary Bladder
- Urinary Bladder Neoplasm
- Neoplasms, Bladder
- Bladder Neoplasms
- Bladder Neoplasm
- Neoplasm, Bladder
- Bladder Tumors
- Bladder Tumor
- Tumor, Bladder
- Tumors, Bladder
Urinary Bladder Cancer- Urinary Bladder Cancer
- Cancer, Urinary Bladder
- Malignant Tumor of Urinary Bladder
- Cancer of the Bladder
- Bladder Cancer
- Bladder Cancers
- Cancer, Bladder
- Cancer of Bladder
|
Below are MeSH descriptors whose meaning is more general than "Urinary Bladder Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Urinary Bladder Neoplasms".
This graph shows the total number of publications written about "Urinary Bladder Neoplasms" by people in this website by year, and whether "Urinary Bladder Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 0 | 3 |
| 2003 | 2 | 0 | 2 |
| 2004 | 3 | 0 | 3 |
| 2005 | 5 | 1 | 6 |
| 2006 | 1 | 0 | 1 |
| 2007 | 6 | 0 | 6 |
| 2008 | 6 | 1 | 7 |
| 2009 | 4 | 0 | 4 |
| 2010 | 3 | 0 | 3 |
| 2011 | 3 | 0 | 3 |
| 2012 | 3 | 1 | 4 |
| 2013 | 3 | 0 | 3 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 3 | 0 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 3 | 0 | 3 |
| 2022 | 2 | 0 | 2 |
| 2023 | 4 | 0 | 4 |
| 2024 | 4 | 1 | 5 |
| 2025 | 3 | 1 | 4 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Urinary Bladder Neoplasms" by people in Profiles.
-
Tang X, Liu L, Gao M, Duan P, Li S, Yuan Z, Xia Q, Xi L, Tan Y. Single-cell transcriptomics identifies fibroblast associated immune heterogeneity and prognostic signatures in bladder cancer. Sci Rep. 2026 Feb 03; 16(1):7151.
-
Mittal K, Mouw KW, Singh P. Circulating Tumor DNA in Urothelial Cancer: Practical Applications in Oncology Clinic. JCO Oncol Pract. 2026 Sep; 22(9):1508-1516.
-
Clements MB, Pekala KR, Tin AL, Sjoberg DD, Beech B, Atkinson T, Herr H, Donat SM, Vickers AJ, Dalbagni G, Bochner BH. Prospective health-related quality of life in women undergoing radical cystectomy and urinary diversion. BJU Int. 2025 Oct; 136(4):728-737.
-
Lee D, Jeon KH, Jung J, Han K, Cho MH, Cho IY, Shin DW. Urological cancer risk in patients with rheumatoid arthritis compared to matched controls: a nationwide cohort study. Rheumatology (Oxford). 2025 06 01; 64(6):3458-3467.
-
Seiden B, Ajay D, Cheung F, Clements M, Pietzak E. Management of Lower Urinary Tract Symptoms during the Treatment for Non-Muscle Invasive Bladder Cancer. Curr Urol Rep. 2025 Jan 06; 26(1):24.
-
Mittal K, Joshi M. Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward. Med. 2024 12 13; 5(12):1449-1451.
-
Moody KA, Iofel SS, Clements MB. Health-Related Quality of Life Across the Spectrum of Bladder Cancer: A Current Review. Curr Urol Rep. 2024 Dec 11; 26(1):21.
-
Dahl DM, Rodgers JP, Shipley WU, Michaelson MD, Wu CL, Parker W, Jani AB, Cury FL, Hudes RS, Michalski JM, Hartford AC, Song D, Citrin DE, Karrison TG, Sandler HM, Feng FY, Efstathiou JA. Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol. 2024 12; 42(34):4095-4102.
-
Khosla H, Bhatt S, Wang MJ, Gignac G, Mittal K, Patel J. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis. J Oncol Pharm Pract. 2024 Jul; 30(5):941-944.
-
Mittal K, Joshi M. FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape. Med. 2024 03 08; 5(3):176-178.